Study of simmitinib versus chemotherapy for advanced esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new targeted drug, simmitinib, compared to standard chemotherapy for people with advanced esophageal squamous cell carcinoma that has progressed after first-line treatment. It aims to see if the new drug can help control the cancer better or with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have esophageal squamous cell carcinoma that is advanced, recurrent, or has spread and can't be surgically removed.
- You have already tried one line of standard chemotherapy (with platinum, taxane, or fluorouracil plus immunotherapy) and it stopped working, or you progressed within 6 months of completing such treatment.
- You are able to walk and take care of yourself (ECOG performance status 0-1).
- You have at least one measurable tumor lesion as seen on scans.
- You have adequate organ function (kidney, liver, blood counts) and are not severely underweight (BMI > 18.5).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment for advanced or metastatic esophageal cancer that has not responded to previous chemotherapy. It aims to see if this treatment can help slow down the cancer or shrink tumors.
This study tests a new treatment for people with locally advanced esophageal cancer that did not respond to initial chemotherapy and immunotherapy. The goal is to see if the study drug can shrink or control the cancer when surgery is not an option.
This trial tests a new drug, QLC5508, against standard chemotherapy for people with advanced esophageal cancer that has already been treated. It aims to see if the new drug works better.
This trial tests different combinations of treatments given before surgery for a type of esophageal cancer called squamous cell carcinoma. It aims to find the best approach to shrink the tumor and improve outcomes for patients whose cancer has not spread to distant organs.
This Phase 2 trial tests penpulimab plus chemotherapy (with or without an added targeted pill called anlotinib) in people with advanced esophageal squamous cell carcinoma. It aims to slow tumor growth and improve outcomes, especially for patients who can’t have curative surgery or radiation.
This trial tests a new treatment plan for people with advanced esophageal squamous cell carcinoma that has spread to lymph nodes but not to other organs. It aims to find the best way to treat this cancer using radiation and other therapies.
Hear when a new Advanced Oesophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.